par Beuselinck, B;Wolter, P;Karadimou, A;Elaidi, R;Dumez, Herlinde;Rogiers, Annick
;Van Cann, T;Willems, L;Body, Jean-Jacques
;Berkers, J;Van Poppel, H;Lerut, E;Debruyne, P;Paridaens, R;Schöffski, P
Référence British Journal of Cancer, 107, 10, page (1665-1671)
Publication Publié, 2012-11
;Van Cann, T;Willems, L;Body, Jean-Jacques
;Berkers, J;Van Poppel, H;Lerut, E;Debruyne, P;Paridaens, R;Schöffski, PRéférence British Journal of Cancer, 107, 10, page (1665-1671)
Publication Publié, 2012-11
Article révisé par les pairs
| Résumé : | The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but also induce osteonecrosis of the jaw (ONJ). |



